How Pharma Bets on the Next Wave (Without Ever Really Knowing)
- Aug 4
- 4 min read
What mega-cap R&D spending on mAbs, ADCs, mRNA, and cell and gene therapy actually signals
Prepared by Richstorm.co
Key Takeaways
Committing capital to a modality is drilling in a promising region, not identifying a specific winning well.
Small molecules and monoclonal antibodies are the most confirmed regions, with gene editing the least confirmed at just one approval.
More confirmed isn't simply better — confirmation and reward move in roughly opposite directions, since proven regions get crowded fast.
A modality being validated doesn't make any specific company's molecule a winner — individual programs still face the same three gates.
Even Flagship Pioneering, the firm credited with backing Moderna, has a sub-1% rate of true outlier outcomes across its own portfolio.
When a mega-cap commits billions to monoclonal antibodies, antibody-drug conjugates, mRNA, or cell and gene therapy, it looks like conviction — like someone finally knows where the next wave is. They don't. What they have is a genuine, evidence-based reason to believe the odds in that area are better than average. That's a different, more honest claim, and it changes what a reader should actually take from watching where the capital goes.
The Oil-Exploration Frame
A geological survey doesn't tell an oil company where the oil is. It tells them a region has better odds than the surrounding ground. So they drill many wells in that region. Most still come up dry. But drilling there beats drilling randomly, over enough wells and enough years.
That's what a mega-cap is doing with a modality. It isn't predicting which molecule wins. It's reading external signals — competitor approvals, proven manufacturing, a licensing deal where a smaller company already cleared the first gate — that say this region is worth several tries. The bet is on the region. The winner, if there is one, still has to be found well by well.
Eight Regions, Ranked by How Confirmed They Are
Applying the frame to where pharma capital actually flows shows modalities sitting at genuinely different stages of confirmation — not equally uncertain bets. Ranking them by approval count gives a concrete, sourced way to see the spread, from the oldest and most proven region down to the newest one with only a single approval on record.
Table: Confirmation stage by modality, most to least confirmed
This isn't exhaustive. Targeted protein degraders, oncolytic viruses, and microbiome therapeutics all have active pipelines but zero or near-zero approvals yet — too little track record to rank meaningfully alongside the regions above.
More Confirmed Isn't Simply Better
It's tempting to read the ranking as a straight scale — the higher a modality sits, the better the bet. That's not right, and the reason is a genuine trade-off, not a caveat.
A confirmed region reduces uncertainty about whether the platform itself works. It says nothing about whether any specific company's molecule inside it wins, and it comes with real costs. A confirmed region is crowded — everyone can see it works, so competitors pile in, and a small-molecule or mAb program competes against dozens of approved drugs and dozens more in development. An unconfirmed region has little to no competition, because most companies aren't there yet.
Confirmation and reward move in roughly opposite directions. Higher confirmation means lower platform risk, but also a lower ceiling and heavier competition. Lower confirmation means higher platform risk, but a bigger prize if a company gets there first — which is exactly why Moderna's unconfirmed mRNA bet paid off as large as it did.
A Real Region Still Doesn't Pick the Well
A modality being validated changes the odds of the region. It does not change the odds of any single company's molecule inside it — every program still has to clear the three gates covered in our earlier piece, Pharma's Predictable Half — and the Coin Flip Hiding Inside It, and most don't. The scale of that miss rate is visible even in firms built specifically to find these bets early: Flagship Pioneering's own hit rate across roughly 148 portfolio companies is a sub-1% rate of true outlier outcomes. A firm embedded in the science, picking within a region it understands deeply, still misses almost every time — that isn't a knock on Flagship, it's the actual base rate of picking individual wells, even for the best-positioned driller in the field.
What a Reader Can Actually Track
An outside reader isn't going to out-predict a mega-cap's R&D team on which specific molecule wins, and shouldn't try. What's available is reading the same regional-confirmation signals a mega-cap reads before it deploys capital:
Is capital following data or narrative — is deal and licensing value rising after real clinical results, or ahead of them? Is the mechanism validated across multiple independent programs, not just one company's asset? Is the addressable population expanding beyond the original niche, the way RNA therapeutics have moved from rare disease into cardiometabolic conditions? And are actual approvals accumulating, not just trial starts?
Those four signals size the region. They never pick the well — that judgment stays a bet for everyone, mega-caps included.
The Closing Scorecard
Confirmable: which regions currently have real signal behind them, and which are still mostly speculative. Not confirmable, for anyone — mega-cap, specialist VC, or individual reader: which specific company's molecule is the one that hits. Billions in R&D spending is a well-informed bet on where to drill. It was never a prediction of which well comes in.
